| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.
|
J Exp Med
|
2007
|
5.22
|
|
2
|
Medicine. The need for a global HIV vaccine enterprise.
|
Science
|
2003
|
4.70
|
|
3
|
Standardization of cytokine flow cytometry assays.
|
BMC Immunol
|
2005
|
4.55
|
|
4
|
Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.
|
Blood
|
2003
|
4.24
|
|
5
|
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses.
|
J Exp Med
|
2008
|
4.21
|
|
6
|
HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.
|
Proc Natl Acad Sci U S A
|
2005
|
4.02
|
|
7
|
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
|
Neurology
|
2012
|
3.63
|
|
8
|
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
|
J Exp Med
|
2008
|
3.42
|
|
9
|
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
|
Lancet
|
2002
|
3.32
|
|
10
|
Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.
|
J Immunol
|
2005
|
3.04
|
|
11
|
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.
|
Nat Med
|
2011
|
2.77
|
|
12
|
Functional signatures of protective antiviral T-cell immunity in human virus infections.
|
Immunol Rev
|
2006
|
2.75
|
|
13
|
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production.
|
J Exp Med
|
2012
|
2.46
|
|
14
|
Inadequate T follicular cell help impairs B cell immunity during HIV infection.
|
Nat Med
|
2013
|
2.29
|
|
15
|
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
|
PLoS Pathog
|
2009
|
2.24
|
|
16
|
Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.
|
J Exp Med
|
2008
|
2.05
|
|
17
|
Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load.
|
Eur J Immunol
|
2004
|
2.05
|
|
18
|
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
|
Lancet Neurol
|
2010
|
2.02
|
|
19
|
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.
|
J Infect Dis
|
2012
|
1.89
|
|
20
|
Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype.
|
Proc Natl Acad Sci U S A
|
2007
|
1.88
|
|
21
|
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.
|
AIDS
|
2003
|
1.81
|
|
22
|
Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication.
|
Eur J Immunol
|
2008
|
1.70
|
|
23
|
IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets.
|
J Allergy Clin Immunol
|
2009
|
1.65
|
|
24
|
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
|
Vaccine
|
2006
|
1.63
|
|
25
|
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.
|
Vaccine
|
2008
|
1.62
|
|
26
|
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.
|
Proc Natl Acad Sci U S A
|
2011
|
1.55
|
|
27
|
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
|
Proc Natl Acad Sci U S A
|
2010
|
1.53
|
|
28
|
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25.
|
Proc Natl Acad Sci U S A
|
2010
|
1.50
|
|
29
|
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.
|
Blood
|
2002
|
1.45
|
|
30
|
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
|
Vaccine
|
2006
|
1.37
|
|
31
|
Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections.
|
Eur J Immunol
|
2002
|
1.34
|
|
32
|
Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure.
|
J Virol
|
2009
|
1.27
|
|
33
|
HIV-1 T-cell vaccines: evaluating the next step.
|
Lancet Infect Dis
|
2007
|
1.27
|
|
34
|
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.
|
J Clin Invest
|
2002
|
1.26
|
|
35
|
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.
|
Vaccine
|
2008
|
1.25
|
|
36
|
Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
|
Brain
|
2008
|
1.24
|
|
37
|
HIV-1 vaccines and adaptive trial designs.
|
Sci Transl Med
|
2011
|
1.21
|
|
38
|
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
|
Vaccine
|
2006
|
1.18
|
|
39
|
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.
|
PLoS One
|
2011
|
1.16
|
|
40
|
Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization.
|
Eur J Immunol
|
2007
|
1.15
|
|
41
|
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
|
Vaccine
|
2011
|
1.15
|
|
42
|
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
|
J Clin Invest
|
2014
|
1.12
|
|
43
|
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
|
J Acquir Immune Defic Syndr
|
2004
|
1.12
|
|
44
|
Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease.
|
Eur J Immunol
|
2013
|
1.12
|
|
45
|
Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.
|
J Virol
|
2009
|
1.11
|
|
46
|
Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
|
Hum Immunol
|
2009
|
1.09
|
|
47
|
De novo T-cell generation in patients at different ages and stages of HIV-1 disease.
|
Blood
|
2004
|
1.07
|
|
48
|
Cytomegalovirus (CMV)-specific cellular immune responses.
|
Hum Immunol
|
2004
|
1.06
|
|
49
|
Improved NYVAC-based vaccine vectors.
|
PLoS One
|
2011
|
1.04
|
|
50
|
Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL-7Ralphahigh cell population in solid organ transplant recipients.
|
J Exp Med
|
2007
|
1.04
|
|
51
|
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors.
|
PLoS One
|
2011
|
1.02
|
|
52
|
Functional avidity: a measure to predict the efficacy of effector T cells?
|
Clin Dev Immunol
|
2012
|
1.01
|
|
53
|
Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression.
|
J Virol
|
2010
|
0.98
|
|
54
|
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.
|
J Virol
|
2011
|
0.97
|
|
55
|
Immune response to HIV.
|
Curr Opin HIV AIDS
|
2013
|
0.97
|
|
56
|
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
|
PLoS One
|
2012
|
0.96
|
|
57
|
Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection.
|
Eur J Immunol
|
2005
|
0.96
|
|
58
|
The functional and structural neural basis of individual differences in loss aversion.
|
J Neurosci
|
2013
|
0.94
|
|
59
|
Intrathecal immune responses to EBV in early MS.
|
Eur J Immunol
|
2010
|
0.94
|
|
60
|
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.
|
Eur J Immunol
|
2012
|
0.94
|
|
61
|
The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.
|
J Virol
|
2012
|
0.94
|
|
62
|
Transepithelial transport of HIV-1 by M cells is receptor-mediated.
|
Proc Natl Acad Sci U S A
|
2002
|
0.94
|
|
63
|
Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure.
|
AIDS
|
2007
|
0.94
|
|
64
|
Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C.
|
PLoS One
|
2013
|
0.92
|
|
65
|
The polymorphic nature of HIV type 1 env V4 affects the patterns of potential N-glycosylation sites in proviral DNA at the intrahost level.
|
AIDS Res Hum Retroviruses
|
2009
|
0.92
|
|
66
|
Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys.
|
J Immunol
|
2010
|
0.92
|
|
67
|
The immune space: a concept and template for rationalizing vaccine development.
|
AIDS Res Hum Retroviruses
|
2014
|
0.92
|
|
68
|
Independent evolution of hypervariable regions of HIV-1 gp120: V4 as a swarm of N-Linked glycosylation variants.
|
AIDS Res Hum Retroviruses
|
2008
|
0.92
|
|
69
|
Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
|
Vaccine
|
2004
|
0.92
|
|
70
|
CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis.
|
Clin Immunol
|
2006
|
0.91
|
|
71
|
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
|
J Clin Invest
|
2014
|
0.88
|
|
72
|
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
|
PLoS One
|
2012
|
0.87
|
|
73
|
Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells.
|
PLoS Pathog
|
2013
|
0.87
|
|
74
|
HIV-1 drug resistance transmission networks in southwest Switzerland.
|
AIDS Res Hum Retroviruses
|
2010
|
0.87
|
|
75
|
Long sequence duplications, repeats, and palindromes in HIV-1 gp120: length variation in V4 as the product of misalignment mechanism.
|
Virology
|
2010
|
0.86
|
|
76
|
Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation.
|
Transpl Int
|
2007
|
0.86
|
|
77
|
Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
|
Vaccine
|
2012
|
0.85
|
|
78
|
Prevalence of anti-HLA antibodies after liver transplantation.
|
Transpl Int
|
2009
|
0.84
|
|
79
|
Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure.
|
J Immunol
|
2011
|
0.84
|
|
80
|
A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response.
|
Vaccine
|
2008
|
0.84
|
|
81
|
Multicenter evaluation of the Elecsys® anti-HCV II assay for the diagnosis of hepatitis C virus infection.
|
J Med Virol
|
2013
|
0.83
|
|
82
|
Intraoral epimucosal fixation for reducible maxillary fractures of the jaws; surgical considerations in comparison to current techniques.
|
J Craniofac Surg
|
2014
|
0.83
|
|
83
|
Clinical studies of experimental vaccines.
|
Curr Opin HIV AIDS
|
2006
|
0.83
|
|
84
|
Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects.
|
J Neuroimmunol
|
2010
|
0.82
|
|
85
|
Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response.
|
J Neuroimmunol
|
2007
|
0.81
|
|
86
|
Natural killer cell receptor--repertoire and functions after induction therapy by polyclonal rabbit anti-thymocyte globulin in unsensitized kidney transplant recipients.
|
Clin Immunol
|
2010
|
0.81
|
|
87
|
Chin Wing Osteotomy for Bilateral Goldenhar Syndrome Treated by "Chin Wing Mentoplasty": Aesthetic, Functional, and Histological Considerations.
|
J Craniofac Surg
|
2015
|
0.81
|
|
88
|
Ridge Expansion by Flapless Split Crest and Immediate Implant Placement: Evolution of the Technique.
|
J Craniofac Surg
|
2016
|
0.81
|
|
89
|
Modulation of human memory T-cell function by different antigen-presenting cells.
|
Eur J Immunol
|
2011
|
0.81
|
|
90
|
Long-term persistence of HIV-1 vaccine-induced CD4+CD45RA-CD62L-CCR7- memory T-helper cells.
|
AIDS
|
2004
|
0.80
|
|
91
|
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
|
Ann Hematol
|
2014
|
0.80
|
|
92
|
HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis.
|
J Immunol
|
2012
|
0.80
|
|
93
|
A Patient With a Rare Single Mandibular Localization of Non-Hodgkin B-Cell Lymphoma: Early Differential Diagnosis With Dental Lesions.
|
J Craniofac Surg
|
2015
|
0.80
|
|
94
|
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.
|
PLoS One
|
2012
|
0.80
|
|
95
|
Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.
|
Antivir Ther
|
2007
|
0.80
|
|
96
|
Monitoring of CD4+CD25highIL-7Rαhigh activated T cells in kidney transplant recipients.
|
Clin J Am Soc Nephrol
|
2011
|
0.80
|
|
97
|
HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment.
|
AIDS
|
2014
|
0.79
|
|
98
|
Carriers of the fragile X mental retardation 1 (FMR1) premutation allele present with increased levels of cytokine IL-10.
|
J Neuroinflammation
|
2012
|
0.79
|
|
99
|
Recurrent brain tumour: the impact of illness on patient's life.
|
Support Care Cancer
|
2011
|
0.79
|
|
100
|
Loss of HIV-1-specific T cell proliferation in chronic HIV-1 infection: cause or consequence of viral replication?
|
AIDS
|
2005
|
0.79
|
|
101
|
Hepatitis C virus infection after liver transplantation is associated with lower levels of activated CD4(+)CD25(+)CD45RO(+)IL-7ralpha(high) T cells.
|
Liver Transpl
|
2010
|
0.79
|
|
102
|
c-Cbl expression levels regulate the functional responses of human central and effector memory CD4 T cells.
|
Blood
|
2008
|
0.79
|
|
103
|
Relationship between structure and CO oxidation activity of ceria-supported gold catalysts.
|
J Phys Chem B
|
2005
|
0.79
|
|
104
|
HIV-1-specific immune response.
|
Adv Pharmacol
|
2008
|
0.78
|
|
105
|
Role of HIV-1-specific CD4 T cells.
|
Curr Opin HIV AIDS
|
2006
|
0.78
|
|
106
|
New Technique for Mandibular Symphyseal Distraction by a Double-Level Anchorage and Fixation System: Advantages and Results.
|
J Craniofac Surg
|
2016
|
0.77
|
|
107
|
Systems biology in the development of HIV vaccines.
|
Curr Opin HIV AIDS
|
2012
|
0.77
|
|
108
|
The impact of an aging population on the diagnosis of pulmonary embolism: comparison of young and elderly patients.
|
Clin Appl Thromb Hemost
|
2007
|
0.77
|
|
109
|
Immune-based interventions in HIV infection: doing the right studies, getting the right answers.
|
AIDS
|
2006
|
0.77
|
|
110
|
Osteodistraction With Dental Implant-Borne Devices for Bone Regeneration in Atrophied Premaxilla.
|
J Craniofac Surg
|
2016
|
0.77
|
|
111
|
MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects.
|
Neurol Sci
|
2012
|
0.77
|
|
112
|
Lifelong dynamics of human CD4+CD25+ regulatory T cells: insights from in vivo data and mathematical modeling.
|
J Theor Biol
|
2010
|
0.76
|
|
113
|
Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma.
|
Anticancer Drugs
|
2015
|
0.76
|
|
114
|
Understanding what makes a good versus a bad vaccine.
|
Eur J Immunol
|
2005
|
0.75
|
|
115
|
Implant prosthetic rehabilitation with bone regenerative techniques after fracture of the upper central incisors.
|
Case Rep Dent
|
2013
|
0.75
|
|
116
|
Effort processes in achieving performance outcomes: interrelations among and roles of core constructs.
|
Behav Brain Sci
|
2013
|
0.75
|
|
117
|
Unsung hero Robert C. Gallo.
|
Science
|
2009
|
0.75
|
|
118
|
Are all donor-specific antibodies detected by solid-phase assay before transplantation clinically relevant?
|
Transplantation
|
2009
|
0.75
|
|
119
|
B-cell abnormalities and impact on antibody response in HIV infection.
|
Curr Opin HIV AIDS
|
2017
|
0.75
|
|
120
|
Metal-support interaction and redox behavior of Pt(1 wt %)/Ce0.6Zr0.4O2.
|
J Phys Chem B
|
2006
|
0.75
|
|
121
|
Antiviral memory T cell responses: correlation with protective immunity and implication for vaccine development.
|
Adv Exp Med Biol
|
2002
|
0.75
|
|
122
|
One year on: vale Joep Lange.
|
Curr Opin HIV AIDS
|
2015
|
0.75
|
|
123
|
Combined sulfating and non-sulfating support to prevent water and sulfur poisoning of Pd catalysts for methane combustion.
|
Chem Commun (Camb)
|
2010
|
0.75
|
|
124
|
Chemical-physical properties of spinel CoMn2O4 nano-powders and catalytic activity in the 2-propanol and toluene combustion: Effect of the preparation method.
|
J Environ Sci Health A Tox Hazard Subst Environ Eng
|
2011
|
0.75
|
|
125
|
Thirty years of HIV: what have we learned?
|
Curr Opin HIV AIDS
|
2013
|
0.75
|
|
126
|
[Immunological signatures: a new tool to diagnose active tuberculosis disease?].
|
Med Sci (Paris)
|
2011
|
0.75
|
|
127
|
B-cell abnormalities and impact on antibody response in HIV infection.
|
Curr Opin HIV AIDS
|
2017
|
0.75
|
|
128
|
Osteodistraction With Dental Implant-Borne Devices for Bone Regeneration in Atrophied Premaxilla.
|
J Craniofac Surg
|
2016
|
0.75
|
|
129
|
A new cell for the study of in situ chemical reactions using X-ray absorption spectroscopy.
|
J Synchrotron Radiat
|
2005
|
0.75
|
|
130
|
Reply to Kadayifci and Yildirim.
|
Endoscopy
|
2016
|
0.75
|
|
131
|
Four-year post-loading results of full-arch rehabilitation with immediate placement and immediate loading implants: A retrospective controlled study.
|
Quintessence Int
|
2017
|
0.75
|
|
132
|
Cytokine mRNA profile of Epstein-Barr virus-stimulated highly differentiated T cells in multiple sclerosis: a pilot study.
|
J Neuroimmunol
|
2010
|
0.75
|
|
133
|
Nonrandom distribution of cryptic repeating triplets of purines and pyrimidines (RNY)(n) in gp120 of HIV Type1.
|
AIDS Res Hum Retroviruses
|
2011
|
0.75
|